FY2027 EPS Estimates for ImmunityBio Lifted by HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Analysts at HC Wainwright upped their FY2027 earnings per share estimates for ImmunityBio in a report released on Tuesday, August 4th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of $0.07 per share for the year, up from their prior estimate of $0.06. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.31) per share.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The business had revenue of $51.24 million during the quarter, compared to analyst estimates of $49.80 million.

A number of other equities research analysts have also issued reports on the stock. D. Boral Capital reissued a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a report on Tuesday, May 5th. BTIG Research reaffirmed a “buy” rating and set a $12.00 target price on shares of ImmunityBio in a research note on Thursday, May 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a report on Friday, July 10th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.20.

ImmunityBio Stock Down 2.8%

NASDAQ IBRX opened at $6.95 on Wednesday. The business’s fifty day simple moving average is $7.68 and its 200-day simple moving average is $7.62. The firm has a market cap of $7.28 billion, a PE ratio of -8.18 and a beta of 0.03. ImmunityBio has a 52 week low of $1.95 and a 52 week high of $12.43.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IBRX. WealthPlan Investment Management LLC acquired a new position in ImmunityBio in the fourth quarter valued at about $27,000. Diversify Advisory Services LLC acquired a new stake in shares of ImmunityBio during the second quarter valued at about $27,000. Kovack Advisors Inc. acquired a new stake in shares of ImmunityBio during the fourth quarter valued at about $27,000. Opal Wealth Advisors LLC purchased a new stake in shares of ImmunityBio in the 4th quarter valued at approximately $28,000. Finally, Empowered Funds LLC purchased a new stake in shares of ImmunityBio in the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Insider Buying and Selling at ImmunityBio

In other ImmunityBio news, Director Cheryl Cohen sold 131,210 shares of ImmunityBio stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $9.50, for a total value of $1,246,495.00. Following the sale, the director owned 125,386 shares in the company, valued at $1,191,167. The trade was a 51.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christobel Selecky sold 159,478 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $9.02, for a total value of $1,438,491.56. Following the completion of the transaction, the director directly owned 35,064 shares in the company, valued at approximately $316,277.28. This trade represents a 81.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,443 shares of company stock worth $3,918,819 over the last quarter. 66.10% of the stock is currently owned by company insiders.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.